The Phase 1b lead-in trial, , which is enrolling up to 18 patients, is intended to identify the optimal dosage of HER-Vaxx for the study’s Phase 2, and to confirm the drug’s safety and immunogenecity. Phase 2 will involve approximately 68 patients and will be an open label study,randomised into two groups: HER-Vaxx plus standard-of-care(chemotherapy) and standard-of-care alone. The endpoints of Phase 2 will be safety, immune response, progression-free survival and overall survival.
all sounds good for moving forward
November News Letter, page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.002(3.70%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.2¢ | $148.9K | 2.828M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 2436853 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 392814 | 5 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |